Cargando…
Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322351/ https://www.ncbi.nlm.nih.gov/pubmed/35891166 http://dx.doi.org/10.3390/vaccines10071002 |
_version_ | 1784756281807994880 |
---|---|
author | Aguilera, Ximena González, Claudia Apablaza, Mauricio Rubilar, Paola Icaza, Gloria Ramírez-Santana, Muriel Pérez, Claudia Cortes, Lina Jimena Núñez-Franz, Loreto Quezada-Gaete, Rubén Castillo-Laborde, Carla Correa, Juan Said, Macarena Hormazábal, Juan Vial, Cecilia Vial, Pablo |
author_facet | Aguilera, Ximena González, Claudia Apablaza, Mauricio Rubilar, Paola Icaza, Gloria Ramírez-Santana, Muriel Pérez, Claudia Cortes, Lina Jimena Núñez-Franz, Loreto Quezada-Gaete, Rubén Castillo-Laborde, Carla Correa, Juan Said, Macarena Hormazábal, Juan Vial, Cecilia Vial, Pablo |
author_sort | Aguilera, Ximena |
collection | PubMed |
description | Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access. |
format | Online Article Text |
id | pubmed-9322351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93223512022-07-27 Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile Aguilera, Ximena González, Claudia Apablaza, Mauricio Rubilar, Paola Icaza, Gloria Ramírez-Santana, Muriel Pérez, Claudia Cortes, Lina Jimena Núñez-Franz, Loreto Quezada-Gaete, Rubén Castillo-Laborde, Carla Correa, Juan Said, Macarena Hormazábal, Juan Vial, Cecilia Vial, Pablo Vaccines (Basel) Brief Report Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access. MDPI 2022-06-23 /pmc/articles/PMC9322351/ /pubmed/35891166 http://dx.doi.org/10.3390/vaccines10071002 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Aguilera, Ximena González, Claudia Apablaza, Mauricio Rubilar, Paola Icaza, Gloria Ramírez-Santana, Muriel Pérez, Claudia Cortes, Lina Jimena Núñez-Franz, Loreto Quezada-Gaete, Rubén Castillo-Laborde, Carla Correa, Juan Said, Macarena Hormazábal, Juan Vial, Cecilia Vial, Pablo Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
title | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
title_full | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
title_fullStr | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
title_full_unstemmed | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
title_short | Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile |
title_sort | immunization and sars-cov-2 antibody seroprevalence in a country with high vaccination coverage: lessons from chile |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322351/ https://www.ncbi.nlm.nih.gov/pubmed/35891166 http://dx.doi.org/10.3390/vaccines10071002 |
work_keys_str_mv | AT aguileraximena immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT gonzalezclaudia immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT apablazamauricio immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT rubilarpaola immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT icazagloria immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT ramirezsantanamuriel immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT perezclaudia immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT corteslinajimena immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT nunezfranzloreto immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT quezadagaeteruben immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT castillolabordecarla immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT correajuan immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT saidmacarena immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT hormazabaljuan immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT vialcecilia immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile AT vialpablo immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile |